Skip to content

FDA Rejects Capricor's Deramiocel BLA a Second Time, Cites Insufficient Effectiveness Data

TAT
Traders Agency TeamThe Traders Agency editorial team delivers daily market anal...
November 21, 2026|4 min read
Two stacked clinical binders with a red seal mark sit under a desk lamp in a dim regulatory office, with blurred medical charts and vials in the background.

Follow Traders Agency on Google. Add us as a preferred source so our market analysis shows up more in your Search and AI results.

Add to Preferred Sources

Capricor Therapeutics said it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration rejecting the resubmitted Biologics License Application for Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy. It is the second time in under two years that the agency has declined to approve the therapy, according to Seeking Alpha and the company's own regulatory update.

What the FDA Said

According to Capricor's press release, the CRL states that the FDA "does not consider the data sufficient to establish substantial evidence of effectiveness" and cites "certain other clinical deficiencies." The company's statement does not specify what those additional deficiencies involve.

Capricor CEO Linda Marbán pushed back on the effectiveness finding, saying Deramiocel was studied in two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, and that both met their primary endpoints. "We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval," Marbán said in the company's release. She added that Capricor is "reviewing the letter carefully and will share next steps once we have completed our evaluation."

Financial Position and Cost Review

Capricor reported that, as of September 30, 2026, it held cash, cash equivalents, restricted cash and marketable securities of approximately $198.5 million, an amount the company said it believes is sufficient to fund planned operations for at least the next 12 months. Separately, the company said it is reviewing its operating costs to further extend its cash runway, a point also noted by Seeking Alpha, which reported that Capricor's operating expenses are under review following the rejection. Capricor's release did not detail specific line items or programs that might be scaled back as part of that review.

What Happens Next

Capricor scheduled a conference call and webcast for Monday, November 23 at 8:30 a.m. ET to discuss the regulatory update. The company's announcement did not address the timing of a resubmission, a potential appeal, or an alternative regulatory pathway.

In its forward-looking statements, Capricor listed "the contents of, and our response to, the Complete Response Letter and the timing of any resubmission," along with its "financial position, cash runway and planned cost reductions," among the matters subject to risks and uncertainties. Read alongside CEO Linda Marbán's statement that the company will "share next steps once we have completed our evaluation," that language suggests — as an interpretation of the disclosure rather than a company statement — that Capricor had not publicly committed to a specific next regulatory move, whether a third BLA submission, a request for a meeting with the FDA, or another route, as of the announcement.

Our Interpretation

Two rejections of the same therapy within roughly two years represent a significant setback for Capricor, whose Deramiocel program has now failed to clear the FDA's effectiveness bar twice, despite the company's own characterization of its trial data as meeting primary endpoints in both HOPE-2 and HOPE-3. The gap between Capricor's confidence in its data and the FDA's conclusion that effectiveness evidence remains insufficient is the central unresolved tension in this story, and in our view it is one that will likely need to be addressed in direct dialogue with the agency before any further submission has a realistic path forward. The vague reference to "certain other clinical deficiencies" without elaboration also leaves outside observers unable to assess how substantial or resolvable those additional issues might be.

On the financial side, a $198.5 million cash position as of September 30, 2026 gives Capricor a buffer it says covers at least 12 months of operations, but the company's own move to review operating costs suggests management is treating the setback as a reason to conserve resources rather than assume a near-term approval and commercial launch. That is a reasonable and cautious posture given the regulatory uncertainty, though it does not by itself indicate how long a renewed review process might take.

Bottom Line

The FDA's second Complete Response Letter for Deramiocel centers on insufficient evidence of effectiveness plus unspecified additional clinical deficiencies, a combination that complicates Capricor's path to approval for a therapy the company maintains met its primary trial endpoints twice. With approximately $198.5 million in cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026 and a cost review underway, Capricor says it has funding for at least 12 months of planned operations, but the company had not detailed its next regulatory step as of its announcement, leaving the timing and shape of any resubmission or alternative pathway an open question pending further disclosure.

DISCLAIMER: Traders Agency does not offer financial advice. The information provided is for educational purposes only and should not be considered financial advice. Traders Agency is not responsible for any financial losses or consequences resulting from the use of the information provided. Trading carries inherent risks and may not be suitable for all individuals. You are advised to conduct your own research and seek personalized advice before making any investment decisions, recognizing the potential risks and rewards involved.

See more from Traders Agency on Google

Make us a preferred source and our market analysis will appear more prominently in your Google Search, Top Stories, and AI results.

Add to Preferred Sources
Traders Agency

Written by

Traders Agency TeamEditorial Team

The Traders Agency editorial team delivers daily market analysis, stock research, and trading education. Our team of analysts covers stocks, options, crypto, commodities, and macroeconomics to help traders make informed decisions.

Join the Edge

Stop watching.
Start winning.

50,000+ traders get our daily brief before the market opens.

Free. No spam. Unsubscribe anytime.

Traders AgencyWhat Customers Say
4.8
1,544